Table 3.

Odds ratios for AD neuropathological scores, vascular brain injury measures, and Athero/arteriosclerosis comparing those exposed to ARBs to those exposed to other antihypertensive medications and those who were not exposed to antihypertensive medications

	ARBs vs other Antihypertensive medications				ARBs vs Untreated
	Univariate		Multivariate*		Univariate		Multivariate*
	OR	CI	OR	CI	OR	CI	OR	CI
CERAD Criteria	0.53	(0.34–0.82)	0.47	(0.27–0.81)	0.48	(0.28–0.82)	0.47	(0.24–0.93)
ADRDA/Khachaturian Criteria	0.51	(0.28–0.93)	0.43	(0.21–0.91)	0.40	(0.19–0.86)	0.49	(0.18–1.30)
BRAAK and BRAAK	0.57	(0.38–0.87)	0.52	(0.31–0.85)	0.62	(0.38–1.02)	0.61	(0.33–1.13)
CERAD Neuritic Plaques Score	0.64	(0.43–0.94)	0.59	(0.37–0.96)	0.47	(0.29–0.75)	0.55	(0.30–1.01)
Large artery infarcts**	1.78	(1.02–3.09)	2.37	(1.15–4.89)	3.34	(1.47–7.61)	3.94	(1.20–13.01)
Micro infarcts/lacunes**	1.01	(0.67–1.52)	1.03	(0.63–1.68)	1.41	(0.85–2.35)	1.10	(0.59–2.04)
Hemorrhage**	2.16	(1.13–4.11)	2.3	(1.11–4.78)	2.73	(1.12–6.65)	2.99	(0.99–8.96)
Atherosclerosis**	1.08	(0.66–1.78)	0.99	(0.52–1.88)	2.31	(1.34–4.0)	1.18	(0.54–2.56)
Arteriosclerosis**	1.18	(0.68–2.03)	1.52	(0.76–3.02)	2.10	(1.15–3.84)	2.4	(1.11–5.18)

CERAD: Consortium to Establish a Registry of Alzheimer’s Disease; ADRDA: Alzheimer's Disease and Related Disorders Association;

^*adjusted for age, gender, systolic blood pressure, BMI, stroke, APOE

^**Also adjusted for anticoagulants/Aspirin